Tremilumab Therapy: Mechanism, Clinical Trials, Efficacy and Safety

Allergy and Clinical Immunology
Tremilumab therapy

Introduction
• Tremilumab is a demonstrated therapeutic activity targeted
for several malignancies. Tremilumab (CP-675,206) a
humanized anti CTLA -4 is an IgG2 antibody having plasma
half life of 22 days
• The therapy has been evaluated on treatment of metastatic
melanoma.
• Phase 1 evaluation indicated maximum tolerable anti
tumour activity.
• In other phase I/II studies reported stable state of disease
occurring in section of melanoma patients treated with
therapy.
• Tremilumab has been utilized and tested on various cancers
both as an immunotherapy and combined therapy forms.

Function and mechanism
• Tremelumab aims at stimulating immune
system which attack on tumours. The cytotoxic
T lymphocytes can recognise and attack
cancer cells.
• It binds to proteins CTLA-4 expressed on the
surface of the activated T- Lymphocytes.
(Eroglu et al.,
2015)